Bottom line
NEQAX vs DODGX: the short answer
NEQAX (Neuberger U.S. Equity Impact Fund) and DODGX (Dodge & Cox Stock Fund) are both mutual funds.
DODGX is cheaper at 0.51% vs 1.27% — a difference of $76 a year per $10,000 invested.
Over one year, DODGX returned +13.7% vs +9.7% for NEQAX (reporting dates differ).
NEQAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
NEQAX vs DODGX side by side
| NEQAX | DODGX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Neuberger Berman Equity | Dodge & Cox |
| Category | Large Blend | Large Blend |
| Expense ratio | 1.27% | 0.51% |
| Annual cost per $10k | $127 | $51 |
| 10-yr cost on $10k (prospectus) | $3,644 | $640 |
| Max front load | 5.75% | 0% |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +9.7% | +13.7% |
| 5-yr return (annualized) | — | +13.3% |
| 10-yr return (annualized) | — | +12.8% |
| Best quarter | +12.5% | +20.9% |
| Worst quarter | −17.2% | −29.2% |
| Net assets (fund) | — | $118.3B |
| Number of holdings | — | 90 |
| Portfolio turnover | 16% | 2% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
NEQAX and DODGX share none of their top holdings.
NEQAX top 10
DODGX top 10
- The Charles Schwab Corp. — 4.00%
- RTX Corp. — 3.75%
- Taiwan Semiconductor Manufacturing Co., Ltd. — 3.54%
- Johnson Controls International PLC — 3.27%
- CVS Health Corp. — 2.77%
- Microsoft Corp. — 2.52%
- Alphabet, Inc. — 2.52%
- MetLife, Inc. — 2.48%
- Humana, Inc. — 2.47%
- Amazon.com, Inc. — 2.17%
FAQ
What is the difference between NEQAX and DODGX?
NEQAX (Neuberger U.S. Equity Impact Fund) and DODGX (Dodge & Cox Stock Fund) are both mutual funds. DODGX is cheaper at 0.51% vs 1.27% — a difference of $76 a year per $10,000 invested.
Which is cheaper, NEQAX or DODGX?
DODGX has the lower expense ratio (0.51%).
Should I own both NEQAX and DODGX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.